Antiangiogenic activity of zoledronic acid: inhibition of the VEGF-VEGFR-2 autocrine loop in the endothelial cells of patients with multiple myeloma

Published: June 8, 2009
Abstract Views: 162
PDF: 157
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Blood vessels are an important component of bone marrow microenvironment in multiple myeloma (MM). Their formation (angiogenesis) parallels the transition from monoclonal gammopathy unassociated/unattributable (MG[u]) to MM, or from remission MM to relapse and the leukemic phase.1,2 The new vessels convey oxygen and metabolites, while endothelial cells (EC) at their tips secrete growth and invasive factors for plasma cells.3

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Vacca, A., Scavelli, C., Di Pietro, G., Cirulli, T., & Ribatti, D. (2009). Antiangiogenic activity of zoledronic acid: inhibition of the VEGF-VEGFR-2 autocrine loop in the endothelial cells of patients with multiple myeloma. Hematology Meeting Reports (formerly Haematologica Reports), 2(3). https://doi.org/10.4081/hmr.v2i3.376